These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
243 related items for PubMed ID: 16880309
21. New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra). Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. J Fam Plann Reprod Health Care; 2004 Jan; 30(1):43-5. PubMed ID: 15006313 [Abstract] [Full Text] [Related]
22. The transdermal contraceptive patch: a new approach to hormonal contraception. Burkman RT. Int J Fertil Womens Med; 2002 Jan; 47(2):69-76. PubMed ID: 11991433 [Abstract] [Full Text] [Related]
23. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Westhoff C, Osborne LM, Schafer JE, Morroni C. Obstet Gynecol; 2005 Jul; 106(1):89-96. PubMed ID: 15994622 [Abstract] [Full Text] [Related]
24. Long-term evaluation of the use of the transdermal contraceptive patch in adolescents. Logsdon S, Richards J, Omar HA. ScientificWorldJournal; 2004 Jul 08; 4():512-6. PubMed ID: 15258678 [Abstract] [Full Text] [Related]
25. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. White T, Jain JK, Stanczyk FZ. Am J Obstet Gynecol; 2005 Jun 08; 192(6):2055-9. PubMed ID: 15970897 [Abstract] [Full Text] [Related]
26. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, Leung AT. J Clin Pharmacol; 2007 Apr 08; 47(4):497-509. PubMed ID: 17389559 [Abstract] [Full Text] [Related]
27. An evaluation of the use of the transdermal contraceptive patch in adolescents. Rubinstein ML, Halpern-Felsher BL, Irwin CE. J Adolesc Health; 2004 May 08; 34(5):395-401. PubMed ID: 15093794 [Abstract] [Full Text] [Related]
28. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. Morin-Papunen L, Martikainen H, McCarthy MI, Franks S, Sovio U, Hartikainen AL, Ruokonen A, Leinonen M, Laitinen J, Järvelin MR, Pouta A. Am J Obstet Gynecol; 2008 Nov 08; 199(5):529.e1-529.e10. PubMed ID: 18533124 [Abstract] [Full Text] [Related]
29. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Contraception; 2005 Sep 08; 72(3):168-74. PubMed ID: 16102549 [Abstract] [Full Text] [Related]
30. Comparing patient telephone callback rates for different hormonal birth control delivery systems. Victor I, Fink RA. Am J Ther; 2006 Sep 08; 13(6):507-12. PubMed ID: 17122531 [Abstract] [Full Text] [Related]
31. Contraceptive use and pregnancy outcome in three generations of Swedish female teenagers from the same urban population. Lindh I, Blohm F, Andersson-Ellström A, Milsom I. Contraception; 2009 Aug 08; 80(2):163-9. PubMed ID: 19631792 [Abstract] [Full Text] [Related]
32. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. Murphy PA, Brixner D. Contraception; 2008 Apr 08; 77(4):257-63. PubMed ID: 18342648 [Abstract] [Full Text] [Related]
33. Factors associated with willingness to use the contraceptive vaginal ring. Gilliam M, Holmquist S, Berlin A. Contraception; 2007 Jul 08; 76(1):30-4. PubMed ID: 17586133 [Abstract] [Full Text] [Related]
34. Contraceptive failure rates in France: results from a population-based survey. Moreau C, Trussell J, Rodriguez G, Bajos N, Bouyer J. Hum Reprod; 2007 Sep 08; 22(9):2422-7. PubMed ID: 17599942 [Abstract] [Full Text] [Related]
35. Preventing unintended pregnancy among young women in Kenya: prospective cohort study to offer contraceptive implants. Hubacher D, Olawo A, Manduku C, Kiarie J, Chen PL. Contraception; 2012 Nov 08; 86(5):511-7. PubMed ID: 22633247 [Abstract] [Full Text] [Related]
36. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A, De Leo V. Minerva Ginecol; 2007 Aug 08; 59(4):415-25. PubMed ID: 17923832 [Abstract] [Full Text] [Related]
37. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Urdl W, Apter D, Alperstein A, Koll P, Schönian S, Bringer J, Fisher AC, Preik M, ORTHO EVRA/EVRA 003 Study Group. Eur J Obstet Gynecol Reprod Biol; 2005 Aug 01; 121(2):202-10. PubMed ID: 16054963 [Abstract] [Full Text] [Related]
38. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Roumen FJ. Contraception; 2007 Jun 01; 75(6):420-9. PubMed ID: 17519147 [Abstract] [Full Text] [Related]
39. Comparative performance of a combined injectable contraceptive (50 mg norethisterone enanthate plus 5mg estradiol valerate) and a combined oral contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in adolescents. Molina RC, Sandoval JZ, Montero AV, Oyarzún PG, Molina TG, González EA. J Pediatr Adolesc Gynecol; 2009 Feb 01; 22(1):25-31. PubMed ID: 19232299 [Abstract] [Full Text] [Related]
40. Prior pill experiences and current continuation among pill restarters. Kalmuss D, Koenemann S, Westhoff C, Heartwell S, Edwards S, Zieman M, Cushman L, Robilotto C, Stuart G. Perspect Sex Reprod Health; 2008 Sep 01; 40(3):138-43. PubMed ID: 18803795 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]